British Journal of CancerLo Nigro C, Vivenza D, Monteverde M, Lattanzio L, Gojis O, Garrone O, Comino A, Merlano M, Quinlan PR, Syed N, Purdie CA, Thompson A, Palmieri C, Crook T (2012) High frequency of complex TP53 mutations in CNS metastases from breast cancer. Br J Cancer 106...
p53, a master regulatory transcription factor, suppresses the proliferative fitness of cancer cells through mechanisms such as cell-cycle arrest, senescence and apoptosis1. Mutations in theTP53gene are observed in about half of all cancers and, as germline mutations, cause Li–Fraumeni syndrome2,3....
2. La Fleur L, Falk-Sörqvist E, Smeds P, et al.Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11[J]. Lung Cancer,...
In the formation of the disease, fallopian tube epithelial (FTE) cells—ovarian cancer progenitor cells—accrue a TP53 mutation and metastasize to the ovary or omentum. To survive in suspension in the peritoneal cavity, FTE cells must evade anoikis, a form of apoptosis that occurs when anchorage...
The mutation/deletion of TP53 was soon demonstrated in many common tumor types (Nigro et al., 1989), and the cancerprone Li-Fraumeni Syndrome, which is characterized by a familial clustering of early (< 45 years) onset tumors, was found to be caused by germline mutations in the TP53 gene...
Cancer Cell 39, 225-239, doi:10.1016/j.ccell.2020.11.013(2021). 11 Tang,Y. et al. Repurposing antiparasitic antimonials to noncovalently rescuetemperature-sensitive p53 mutations. Cell Rep. 39, 110622,doi:10.1016/j.celrep.2022.110622 (2022). 12 Yu,X., Vazquez, A., Levine, A. J. & ...
To uncover a novel mechanism by which mutant TP53 exhibits its gain-of-function properties, we looked for TP53R273Hinteracting proteins that contribute to cancer cell invasion. R273H mutation is one of the hotspot mutations inTP53in human cancers.8,11,12We first conducted a large-scale co-imm...
Both TP53 and ESR1 mutations occur frequently in estrogen receptor positive (ER+) metastatic breast cancers (MBC) and their distinct roles in breast cancer tumorigenesis and progression are well appreciated. Recent clinical studies discovered mutual excl
Somatic Mutations in Cancer (COSMIC) mutational signatures database9,10, we developed a statistical model that describes the TP53 mutational spectrum as a function of the baseline probability of acquiring each mutation and the fitness advantage conferred by attenuation of p53 activity. Collectively, ...
Mutations in TP53 block its tumour suppressive functions by preventing it from binding to target DNA sequences and upregulating genes that mediate several cellular processes, including apoptosis, cell cycle arrest and senescence. Mutant TP53 proteins are also reported to have gain-of-function properties...